JCDR - Register at Journal of Clinical and Diagnostic Research
Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X
Radiology Section DOI : 10.7860/JCDR/2020/31898.13862
Year : 2020 | Month : Jul | Volume : 14 | Issue : 07 Full Version Page : TC10 - TC14

Role of TRUS and MRI in the Detection of Prostate Cancer-A Prospective Study

Kanika Bhambri1, Alok Kumar Pandey2, Anupam Jhobta3, Amit Bhambri4, Sanjiv Sharma5, Balraj Singh6, Kailash Barwal7

1 Senior Resident, Department of Cardiac Radiology, AIIMS, New Delhi, India.
2 Senior Resident, Department of General Surgery, AIIMS, New Delhi, India.
3 Associate Professor, Department of Radiology, IGMC, Shimla, India.
4 Senior Resident, Department of General Surgery, AIIMS, New Delhi, India.
5 Professor, Department of Radiology, IGMC, Shimla, India.
6 Associate Professor, Department of Community Medicine, IGMC, Shimla, India.
7 Assistant Professor, Department of Urology, IGMC, Shimla, India.


NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR: Kanika Bhambri, K-3, Second Floor, South Extension, Part 2, New Delhi, India.
E-mail: kanikabhambri18@gmail.com
Abstract

Introduction

Prostate cancer ranks divond among all cancers affecting men. Common diagnostic tests like Transrectal Ultrasound (TRUS) and Prostate-Specific Antigen (PSA) are suboptimal for diagnostic purpose. Magnetic Resonance Imaging (MRI) has a promising role in detection, guidance for targeted biopsy and staging of prostate cancer.

Aim

To evaluate the role of TRUS and MRI in the detection of prostate cancer and to ascertain if any functional parameter or union of parameters is of any utility in detection of prostate cancer.

Materials and Methods

A prospective study was conducted which included fifty patients who underwent TRUS and 1.5-T MRI before being subjected toTRUS-guided biopsy. Imaging was compared with histopathological results. The sensitivity, specificity, positive and negative predictive value, positive and negative likelihood ratio for each of the investigation was calculated.

Results

The accuracy of the model combining all the imaging variables {T2-weighted imaging (T2WI), MR spectroscopy (MRS), Diffusion-Weighted Imaging (DWI), Apparent Diffusion Coefficient (ADC) and Dynamic Contrast-Enhanced (DCE) MRI} in predicting prostate cancer was 94%, which was higher than the diagnostic accuracy of each variable considered alone (DWI, 92%; ADC, 92%; MRS, 88.0%; DCE-MRI, 92%; and T2WI, 72%). TRUS had a diagnostic accuracy of 80%, sensitivity of 100.0%, specificity of 67.7%, PPV of 65.5% and NPV of 100.0%.

Conclusion

TRUS had a high sensitivity and negative predictive value but a low specificity. MRI had both high sensitivity and specificity especially when the combination of functional sequences was used. But, the addition of a third functional technique does not further improve detection. Thus, a limited number of functional sequences are needed in every MRI study for prostatic cancer. However, DWI being the most valuable should be included as one of the sequences.

Keywords

Introduction

Prostate cancer is next only to lung cancer among all the cancers affecting men [1]. Conventional diagnostic methods such as PSA and TRUS have facilitated the detection of early-stage prostate cancer. However, the accuracy of both methods is suboptimal [2]. The sensitivity of PSA as a screening method was highest when used for people between 65-69 years at 24% for PSA cut-off levels 4 ng/mL. Sensitivity was least when used for people belonging to the age group of 50-54 at 9% for PSA cut-off levels of 4 ng/mL [3].

Although TRUS is recognised as the method of choice for biopsy guidance, its low Positive Predictive Value (PPV) in diagnosing malignancy is a major drawback [4].

Because of the limitations of PSA, TRUS, and TRUS-guided biopsy, there is a need for further imaging. MRI is emerging as a powerful modality with recent MRI techniques, like MRS, DWI, or DCE for detecting early prostate cancer [5]. However, it is important to optimise MRI protocols and lower costs by including only necessary sequences in a prostate study. The present study was conducted with an aim to determine the use of TRUS and MRI in the detection of prostate cancer.

Materials and Methods

This prospective cross-sectional study was conducted in Indira Gandhi Medical College and Hospital, Shimla (Himachal Pradesh) among patients attending Urology Department from June 2012 to June 2013. It was approved by our institutional review board. The sample size was determined using the formula n=Z2P (1-P)/d2, where n=sample size, Z=Statistic for a level of confidence, P=Expected prevalence or proportion, d=Precision, with the above assumption and a margin of error of +5%. Sampling was done using simple sampling technique and minimum sample size required was 45. A total of 50 consecutive patients (mean age, 67 years; range, 50-85 years) were included in the study after informed consent. The inclusion criteria were: PSA levels >4 ng/mL, abnormal Digital Rectal Examination (DRE), and any suspicious prostatic lesion on transabdominal or transrectal sonography. Exclusion criteria were patients who have undergone prostate biopsy within three weeks, prostatitis, known case of prostate cancer, contraindications to MRI (e.g., cardiac pacemakers and intracranial clips), urinary tract infection and deranged coagulation profile. All the patients underwent TRUS and MRI examination followed by TRUS guided biopsy.

TRUS Technique

TRUS was done on Xario XG Toshiba machine by a transrectal probe of 6-9 MHz. Any focal hypoechoic or hyperechoic area, regions of mass effect and increased flow were evaluated by Doppler.

MRI Technique

MRI was performed on a 1.5-T whole-body MRI unit (Avanto, Siemens). Body coil was used for excitation, and pelvic phased-array coil was used for signal reception. Transverse, coronal and sagittal high resolution fast spin-echo T2WI of the prostate and seminal vesicles was performed with the following parameters: 5500/101; section thickness, 5 mm; intersection gap, 0 mm; field of view, 200 mm; matrix, 192×320. DWI was performed using a single-shot echoplanar imaging technique with the following parameters: 4300/84; section thickness, 4 mm; intersection gap, 0 mm; average, 4; bandwidth, 1446 Hz.

MRS data was obtained for a volume of the prostate after critically reviewing the transverse T2WI scans. Areas with high values for choline, citrate, and creatine were calculated using numeric integration. Metabolic ratio was obtained for citrate to choline plus creatine. The MRS data were acquired using the following parameters: TR/TE, 690/120; Scan resolution, 10×10×10; Average, 6; Acquisition time, 6 minutes 14 seconds.

After obtaining MRS data, DCE-MRI images were obtained using a multisection T1-weighted 3D vibe sequences with the following parameters: 5.43/2.5; flip angle, 10°; section thickness, 2.5 mm; distance factor, 20; field of view, 350 mm; matrix, 125×256 in the axial plane before and 18 times during IV bolus injection of gadopentetate dimeglumine without delay. About 15 mL of contrast was given at a rate of 3 mL/s followed by 15 mL of saline flush.

TRUS Guided Biopsy

A systematic 12 core biopsy was taken, 6 cores from the base, mid- gland and apex of the Peripheral Zone (PZ) bilaterally, four cores from the PZ in the bilateral margin and the remaining two cores from the Transitional Zone (TZ) bilaterally. One or two core biopsies were taken from any suspicious lesion on grayscale TRUS, Power Doppler Ultrasound (PDUS) and MRI. The biopsy samples were labelled according to the gland region they were obtained from and were sent in 10% formalin solution for histologic examination.

Histopathological Examination

Histological analysis was performed by the same pathologist using a standard method for preparation and staining of the tissue slices. The stain used was Haematoxylin and Eosin (H&E). The grade of the tumour was evaluated and given a standard Gleason score [6].

Quality Control

Patients underwent TRUS by an individual observer. MRI examination was done subsequently and was interpreted by a separate observer who was blinded to the findings of TRUS.

Image Interpretation

On TRUS, the prostate gland was evaluated for the presence of any focal lesion and their echo pattern, capsular integrity, the contour of the gland and extension of the disease process outside the limits of the gland margin. PDUS images were thoroughly analysed, and the vascularity was graded in the following manner: 0-No abnormal vascularity; 1-Low focal vascular clustering; 2-Intensive focal vascular clustering; 3-Diffuse vascular clustering. Grade 0 was considered negative, and 1, 2 and 3 grades were considered positive [7].

On MRI, the following criteria were regarded as prostate cancer:

(i) T2WI: A low signal intensity lesion within the peripheral or TZ, ill-defined prostatic margins and lack of capsule.

(ii) DWI and ADC maps: An area with focal signal hyperintensity on DWI and hypointensity on ADC relative to background prostatic parenchyma.

(iii) MRS: Voxels with Cit/(Cho+Cr) ratio <1.4 were taken as indicative of malignancy.

(iv) DCE-MRI: Early nodular enhancement (before the enhancement of the rest of the prostatic fossa and pelvic muscles) with early washout was interpreted as positive. Also, the presence, asymmetry and degree of enhancement was assessed.

Time-signal intensity curves from DCE-MRI were constructed, which were classified as follows:

1) Type 1- persistent enhancement (benign).

2) Type 2- early fast enhancement which is followed by a plateau phase in which signal intensity remained constant within the acquisition time with no more than 10% change from the peak enhancement (malignant).

3) Type 3- early fast enhancement followed by washout greater than 10% decrease in signal intensity after the peak enhancement (malignant).

Statistical Analysis

The data was analysed using Epi Info Version 7.0.9.7 for Windows. The sensitivity, specificity, PPV, NPV, likelihood ratio positive and likelihood ratio negative for each of the investigation was calculated and 95% confidence intervals around the point estimates were constructed.

Results

Histopathologic analysis detected prostate cancer in 19 (38%) of the 50 patients. Gray scale TRUS detected hypoechoic lesions in 29 patients out of which 19 (38%) were malignant [Table/Fig-1]. All the patients with loss of capsular integrity, contour distortion and extraprostatic extension on TRUS had malignancy with a specificity and PPV of 100% [Table/Fig-2]. PDUS positive areas were determined in 20 cases out of which 17 cases were positive for malignancy on HPE. According to vascularisation grading, 30 cases (60%) were identified as negative (grade 0) out of which 2 cases were malignant. PDUS had an accuracy of 92% in determining the site of suspicious areas with a specificity of 95.7% and PPV of 89.3%[Table/Fig-3].

Trans-Rectal Ultra-Sonographic (TRUS) - gray scale findings.

FindingAll participants (n=50)Malignant (n=19)Benign (n=31)
No.%No.%No.%
Hypoechoic pattern2958.01938.01020.0
Loss of capsular integrity right hemi-prostate816.0816.000.0
Loss of capsular integrity left hemi-prostate510.0510.000.0
Contour distortion right hemi-prostate816.0816.000.0
Contour distortion left hemi-prostate510.0510.000.0
Extra-prostatic extension right hemi-prostate714.0714.000.0
Extra-prostatic extension left hemi-prostate48.048.000.0

Sensitivity, specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV) and likelihood ratios of positive and negative tests of gray scale Trans-Rectal Ultrasonographic (TRUS) parameters with histo-pathologic findings as gold standard.

ParameterDiagnostic accuracy (%)SensitivitySpecificityPPVNPVLHP1LHN2
%95% CI3%95% CI%95% CI%95% CIEstimate95% CIEstimate95% CI
Size of the lesion >1 cm76.080.062.7-90.574.363.0-83.157.142.2-70.989.779.2-95.23.12.7-3.50.270.19-0.38
Hypoechoic pattern80.0100.083.2-100.067.750.1-81.465.547.3-80.1100.084.5-100.03.12.6-3.80.000.0-?
Loss of capsular integrity86.053.336.1-69.8100.094.8-100.0100.080.6-100.083.374.0-89.8UndefinedUndefined0.470.41-0.54
Contour distortion83.043.327.4-60.8100.094.8-100.0100.077.2-100.080.570.9-87.4UndefinedUndefined0.570.51-0.64
Extra-prostatic extension81.036.721.9-54.5100.094.8-100.0100.074.1-100.078.769.1-85.9UndefinedUndefined0.630.57-0.70

(n=100; 50 for each hemiprostate)

1LHP: Likelihood ratio of a positive test; 2LHN: Likelihood ratio of a negative test; 3CI: Confidence interval


Sensitivity, specificity, Positive Predictive Value (PPV). Negative Predictive Value (NPV) and likelihood ratios of positive and negative tests of power doppler trans-rectal ultrasonographic parameters with histo-pathologic findings as gold standard.

ParameterDiagnostic accuracy (%)SensitivitySpecificityPPVNPVLHP4LHN5
%95% CI6%95% CI%95% CI%95% CIEstimate95% CIEstimate95% CI
Site of suspicious area (n=100;Rt hemi-prostate=50,Lt hemi-prostate=50)92.083.366.4-92.795.788.1-98.589.372.8-96.393.184.8-97.019.410.0-38.00.170.12-0.26
Grades 1-3 (n=50)90.089.568.6-97.190.375.1-96.785.064.0-94.863.378.7-98.29.34.8-18.00.120.04-0.31

4LHP: Likelihood ratio of a positive test; 5LHN: Likelihood ratio of a negative test; 6CI: Confidence interval


Magnetic Resonance Imaging

All the patients with malignancy were diagnosed as adenocarcinoma and grading was done according to Gleason system. Perineural invasion was present in 8 (42.1%) cases. All the target biopsies taken from suspicious areas detected on MRI were positive for malignancy.

DWI, ADC, MRS and DCE-MRI had very high likelihood ratio of the positive test as compared to T2WI. T2WI and DCE-MRI had very high likelihood ratio of a negative test [Table/Fig-4]. The combinations of DWI+DCE-MRI and ADC+DCE-MRI an MRS+DCE-MRI had the highest likelihood ratios for positive tests and T2WI+DCE-MRI had the highest likelihood ratios for negative tests amongst the models combining two variables [Table/Fig-5]. The combinations of T2WI+DWI+DCE-MRI, T2WI+ADC+DCE-MRI, The DWI+ADC+DCE-MRI had highest likelihood ratios for positive tests and T2WI+DWI+ADC, T2WI+DWI+DCE and DWI+ADC+DCE had the highest likelihood ratios for negative tests amongst the models combining three variables [Table/Fig-6].

Sensitivity, specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV) and likelihood ratios of positive and negative tests of dichotomised imaging variables on MRI in comparison with histo-pathologic findings as gold standard.

Imaging variableDiagnostic accuracy (%)SensitivitySpecificityPPV7NPV8LHR9 (Positive)LHR10 (Negative)
%95% CI11%95% CI%95% CI%95% CIEstimate95% CIEstimate95% CI
Individual variables
T2W11272.0100.083.2- 100.054.837.8-70.857.640.8-72.8100.081.6-100.02.21.9-2.60.00.0-?
DWI92.094.775.4-99.190.375.1-96.785.765.4-95.096.682.8-99.49.85.1-18.90.060.01-0.42
ADC92.094.775.4-99.190.375.1-96.785.765.4-95.096.682.8-99.49.85.1-18.90.060.01-0.42
MRS88.084.262.4-94.590.375.1-96.784.262.4-94.590.375.1-96.78.74.4-17.10.180.09-0.34
DCE13-MRI92.0100.083.2- 100.087.171.2-94.982.662.9-93.0100.087.5-100.07.84.8-12.70.00.0-?

(n=50)

7PPV: Positive predictivevalue; 8NPV: Negative predictivevalue; 9LHR (Positive): Likelihood ratio of a positive test; 10LHR (Negative): Likelihood ratio of a negative test.

11CI: Confidence interval; 12T2W1 dichotomized on the basis oflow signal intensity in peripheral or transitional zone; 13Dichotomized on the basis of asymmetry of enhancement in either hemi-prostate


Sensitivity, specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV) and likelihood ratios of positive and negative tests of two dichotomised imaging variable combinations on MRI with histo-pathologic findings as gold standard.

Imaging variableDiagnostic accuracy (%)SensitivitySpecificityPPV14NPV15LHR16 (Positive)LHR17 (Negative)
%95% CI18%95% CI%95% CI%95% CIEstimate95% CIEstimate95% CI
Two variable combinations
T2W1+DWI92.094.775.4-99.190.375.1-96.785.765.4-95.096.682.8-99.49.85.1-18.90.060.01-0.42
T2W1+ADC92.094.775.4-99.190.375.1-96.785.765.4-95.096.682.8-99.49.85.1-18.90.060.01-0.42
T2W1+MRS88.084.262.4-94.590.375.1-96.784.262.4-94.590.375.1-96.78.74.4-17.10.180.09-0.34
T2W1+DCE-MRI92.0100.083.2-100.087.171.2-94.982.662.9-93.0100.087.5-100.07.84.8-12.70.00.0-?
DWI+ADC92.094.775.4-99.190.375.1-96.785.765.4-95.096.682.8-99.49.85.1-18.90.060.01-0.42
DWI+MRS94.084.262.4-94.5100.089.0-100.0100.080.6-100.091.277.0-97.0UndefinedUndefined0.160.08-0.30
DWI+DCE-MRI94.094.775.4-99.193.679.3-98.290.069.9-97.296.783.3-99.414.75.5-39.40.060.01-0.40
ADC+MRS94.084.262.4-94.5100.089.0-100.0100.080.6-100.091.277.0-97.0UndefinedUndefined0.160.08-0.30
ADC+DCE-MRI94.094.775.4-99.193.679.3-98.290.069.9-97.296.783.3-99.414.75.5-39.40.060.01-0.40
MRS+DCE-MRI90.084.262.4-94.593.679.3-98.289.067.2-96.990.675.8-96.813.14.8-35.60.170.09-0.33

(n=50)

14PPV: Positive predictive value; 15NPV: Negative predictive value; 16LHR (Positive): Likelihood ratio of a positive test; 17LHR (Negative): Likelihood ratio of a negative test; 18CI: Confidence interval


Sensitivity, specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV) and likelihood ratios of positive and negative tests of three dichotomised imaging variable combinations on MRI in comparison with histo-pathologic findings as gold standard.

Imaging variableDiagnostic accuracy (%)SensitivitySpecificityPPV19NPV20LHR21 (Positive)LHR22 (Negative)
%95% CI23%95% CI%95% CI%95% CIEstimate95% CIEstimate95% CI
Three variable combinations
T2W1+DWI+ADC92.094.775.4-99.190.375.1-96.785.765.4-95.096.682.8-99.49.85.1-18.90.060.01-0.42
T2W1+DWI+MRS94.084.262.4-94.5100.089.0-100.0100.080.6-100.091.277.0-97.0UndefinedUndefined0.160.08-0.30
T2W1+DWI+DCE94.094.775.4-99.193.679.3-98.290.069.9-97.296.783.3-99.414.75.5-39.40.060.01-0.40
T2W1+ADC+MRS94.084.262.4-94.5100.089.0-100.0100.080.6-100.091.277.0-97.0UndefinedUndefined0.160.08-0.30
T2W1+ADC+DCE94.094.775.4-99.193.679.3-98.290.069.9-97.296.783.3-99.414.75.5-39.40.060.01-0.40
T2W1+MRS+DCE90.084.262.4-94.593.679.3-98.289.067.2-96.990.675.8-96.813.14.8-35.60.170.09-0.33
DWI+ADC+MRS94.084.262.4-94.5100.089.0-100.0100.080.6-100.091.277.0-97.0UndefinedUndefined0.160.08-0.30
DWI+ADC+DCE94.094.775.4-99.193.679.3-98.290.069.9-97.296.783.3-99.414.75.5-39.40.060.01-0.40
ADC+MRS+DCE94.084.262.4-94.5100.089.0-100.0100.080.6-100.091.277.0-97.0UndefinedUndefined0.160.08-0.30
MRS+DWI+DCE94.084.262.4-94.5100.089.0-100.0100.080.6-100.091.277.0-97.0UndefinedUndefined0.160.08-0.30

(n=50)

19PPV: Positive predictive value; 20NPV: Negative predictive value; 21LHR (Positive): Likelihood ratio of a positive test; 22LHR (Negative): Likelihood ratio of a negative test; 23CI: Confidence interval


The combination of T2W1+DWI+ADC+DCE-MRI had the highest likelihood ratios for positive tests, and T2WI+DWI+ADC+DCE had the highest likelihood ratio for negative tests amongst the models combining four variables [Table/Fig-7].

A 74-year-old male with adenocarcinoma prostate(gleason score 7) with positive MRI results on T2WI, MR Spectroscopy (MRS), Diffusion-Weighted Imaging (DWI), and Dynamic Contrast-Enhanced (DCE) MRI images. Patient’s PSA level was 243.7 ng/mL.

Imaging variableDiagnostic accuracy (%)SensitivitySpecificityPPV24NPV25LHR26 (Positive)LHR27 (Negative)
%95% CI28%95% CI%95% CI%95% CIEstimate95% CIEstimate95% CI
Fourvariable combinations
T2W1+DWI+ADC+MRS94.084.262.4-94.5100.089.0-100.0100.080.6-100.091.277.0-97.0UndefinedUndefined0.160.08-0.30
T2W1+DWI+ADC+DCE94.094.775.4-99.193.679.3-98.290.069.9-97.296.783.3-99.414.75.5-39.40.060.01-0.40
DWI+ADC+MRS+DCE94.084.262.4-94.5100.089.0-100.0100.080.6-100.091.277.0-97.0UndefinedUndefined0.160.08-0.30
All five variables94.084.262.4-94.5100.089.0-100.0100.080.6-100.091.277.0-97.0UndefinedUndefined0.160.08-0.30

24PPV: Positive predictive value; 25NPV: Negative predictive value; 26LHR Positive: Likelihood ratio of a positive test; 27LHR Negative: Likelihood ratio of a negative test; 28CI: Confidence interval


The accuracy of model combining all the imaging variables (T2WI, MRS, DWI, ADC and DCE-MRI) in predicting prostate cancer was 94%, which was significantly higher than the diagnostic accuracy of each variable considered alone (DWI, 92%; ADC, 92%; MRS, 88.0%; DCE-MRI, 92%; and T2WI, 72%) [Table/Fig-4,7,8].

A 74-year-old male with adenocarcinoma prostate (gleason score 7) with positive MRI results on T2WI, MR Spectroscopy (MRS), Diffusion-Weighted Imaging (DWI), and Dynamic Contrast-Enhanced (DCE) MRI images. Patient’s PSA level was 243.7 ng/mL. a) Axial T2WI shows diffusely hypointense central as well as peripheral zone bilaterally. b) MRS image shows pathologic metabolic curve with reduced citrate and choline peak. Ci/Cho+Cr=0.04. c,d) DWI and ADC show restricted diffusion in the peripheral zone on the right side. e) DCE-MRI image shows curve type 3 from Region Of Interest (ROI) of lesion.

On TRUS (not shown), hypoechoic area was present in right peripheral zone. It showed increased vascularity and was assigned grade 2.

Discussion

In elderly men with an elevated level of serum PSA level, the probable prostate cancer should be localised and detected in the treatable stages. Up to 25% of cancers have a normal PSA level, and greater than 50% have normal DRE result. There was need for an additional diagnostic technique because of the lower sensitivity and specificity of TRUS [8,9].

The purpose of our study was to evaluate and optimise the most efficient MR sequences; T2WI, DCE-MRI, DWI, ADC mapping sequences and H-MRS for detecting the malignancy of the prostate gland.

Transrectal Ultrasound

In our study, TRUS had a diagnostic accuracy of 80%, a sensitivity of 100.0%, a specificity of 67.7%, a PPV of 65.5% and NPV of 100.0%. In a study by Song JM et al., the overall sensitivity, specificity and percent agreement (range) for TRUS were 73.6% (60.0% to 93.3%), 61.3% (26.5% to 91.7%), and 64.6% (37.0% to 92.2%), respectively [10]. Hypoechoic lesions of prostate detected by TRUS, correspond to a wide spectrum of pathologies such as prostatic carcinoma, prostate dysplasia, inflammatory changes, granulomatous prostatitis or benign prostatic hyperplastic nodules. TRUS has high sensitivity for detecting lesion but has very poor specificity.

Power Doppler

PDUS helps in improving the sensitivity of endorectal ultrasound even though it gives some false-negative results. It helps in visualisation of tumour vascularity, capsular extension and also aids in doing image-guided biopsies [11].

In the present study, PDUS had a diagnostic accuracy of 90% in determining prostate cancer with a specificity of 90.3%. In a survey by Boukadoum N et al., power Doppler showed a sensitivity of 44%, specificity of 96%, PPV of 84% and NPV of 80%. There was a positive correlation between power Doppler US and high Gleason scores. On correlating Doppler findings and Gleason scores, they found 86% of hypervascular lesions on power Doppler had a Gleason score of ≥7 compared to 26% of non-vascular malignant nodules [11]. In the present study, we found that 68% of hypervascular lesions on power Doppler had a Gleason score ≥7. KahramanT et al., in a study of 76 patients concluded that PDUS identified a higher number of cases as compared to grayscale imaging cases. PDUS had a higher sensitivity and specificity than TRUS (43% and 60%, respectively) and was able to identify cases with greater accuracy. When both TRUS and PDUS are used as a combined modality, it increases the cancer detection rate with a greater number of biopsies from the suspicious hypervascular foci [7].

In the present study, our goal was to evaluate the practical utility and limitation of PDUS guided biopsy by comparing it with grayscale TRUS and systematic TRUS guided biopsy. PDUS had a higher specificity but lower sensitivity than TRUS (67.7% and 100.0%, respectively). The diagnostic accuracy of PDUS was also higher than TRUS (90.0% vs 80.0%). They found that 17 of 20 hypoechoic hypervascular lesions were cancerous (34%), which suggested that biopsies should be taken both from PDUS and gray scale TRUS positive areas. These findings support the superiority of PDUS over TRUS in the selection of potential biopsy foci.

Reinsberg SA et al., showed that the combination of MRS and DWI increases the specificity of prostate cancer detection while retaining sensitivity compared with MRS alone or DWI alone. Similar results were observed in our present study [12].

When all the parameters of imaging are combined (T2WI, MRS, DWI, ADC and DCE-MRI) the accuracy was 94% which is very much increased when compared with the accuracy of individual parameter alone. The highest accuracy achieved with a combination of two imaging variables was 94% seen with combination of DWI+MRS, DWI+DCE-MRI, ADC+MRS and ADC+DCE-MRI. In present study no significant improvement was observed by the addition of third functional parameter. However DWI should be one of the sequences included.

In a previous study, to evaluate the value of including all three functional sequences, XZ Ma et al., also concluded that combining only two functional parameters led to a significant improvement in prostate cancer detection against the use of a single parameter and that addition of a third parameter does not further improve detection [13].

Our results can help optimise MRI protocols which will lead to cost-reduction by not including only the necessary sequences. As MRS is not widely available and also has the drawback of lacking a standardised evaluation method to ensure reproducibility, we strongly suggest that the protocol for prostate cancer detection should include at least one of either DWI or DCE-MRI sequence or a combination of both. DWI was the most accurate imaging predictor when considered individually, and it was also included in all the best models in our study.

Limitation(s)

One of the main limitations was the correlation of the imaging findings with the pathology findings: none of the patients underwent prostatectomy, so the imaging-histologic correlation in the 50 patients was based solely on the biopsy results. Secondly, correlations between the Gleason’s scores and the MRI findings were not fully investigated. Thirdly, most of our cases with malignancy were in an advanced stage with extraprostatic extension. Finally, larger studies are necessary to further validate our study.

Conclusion(s)

Routine prostate imaging protocol plus dynamic and functional MRI could be applied to patients with increasing PSA levels and abnormal DRE to evaluate the location of the tumour and its spread to neurovascular bundles and prostatic capsule. DWI could represent a non-invasive single diagnostic tool not only in the detection and localisation of prostate cancer but also in prediction of Gleason score. In summary, we have shown that adding data from a third functional technique does not further improve detection.

(n=100; 50 for each hemiprostate)1LHP: Likelihood ratio of a positive test; 2LHN: Likelihood ratio of a negative test; 3CI: Confidence interval4LHP: Likelihood ratio of a positive test; 5LHN: Likelihood ratio of a negative test; 6CI: Confidence interval

References

[1]Rawla P, Epidemiology of prostate cancer World J Oncol 2019 10(2):63-89.10.14740/wjon119131068988  [Google Scholar]  [CrossRef]  [PubMed]

[2]Liau J, Goldberg D, Arif-Tiwari H, Prostate cancer detection and diagnosis: Role of ultrasound with MRI correlates Curr Radiol Rep 2019 7(7)10.1007/s40134-019-0318-8  [Google Scholar]  [CrossRef]

[3]Leal J, Welton NJ, Martin RM, Donovan J, Hamdy F, Neal D, Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study Cancer Epidemiol 2018 52:99-105.10.1016/j.canep.2017.12.00229278842  [Google Scholar]  [CrossRef]  [PubMed]

[4]Tamsel S, Killi R, Hekimgil M, Altay B, Soydan S, Demirpolat G, Transrectal ultrasound in detecting prostate cancer compared with serum total prostate-specificantigen levels Journal of Medical Imaging and Radiation Oncology 2008 52:24-28.10.1111/j.1440-1673.2007.01906.x18373822  [Google Scholar]  [CrossRef]  [PubMed]

[5]Moses DA, Editorial for “Prostate Cancer Risk Stratification in Men With a Clinical Suspicion of Prostate Cancer Using a Unique Biparametric MRI and Expression of 11 Genes in Apparently Benign Tissue: Evaluation Using Machine-Learning Techniques.” Journal of Magnetic Resonance Imaging 2020 51(5)Wiley:1554-55.10.1002/jmri.2713532190936  [Google Scholar]  [CrossRef]  [PubMed]

[6]Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, ISUP Grading CommitteeThe 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Am J Surg Pathol 2005 29(9):1228-42.10.1097/01.pas.0000173646.99337.b116096414  [Google Scholar]  [CrossRef]  [PubMed]

[7]Kahraman T, Cubuk R, Sinanoglu O, Tasalı N, Ozarar M, Saydam B, Comparison of power Doppler ultrasound with gray scale transrectal ultrasound in predicting cancer positive prostate biopsy cores Eurasian J Med 2010 42(2):81-85.10.5152/eajm.2010.2325610129  [Google Scholar]  [CrossRef]  [PubMed]

[8]Aydnn H, Kizilgoz V, Tatar IG, Damar C, Ugan AR, Paker I, Detection of prostate cancer with magnetic resonance imaging: optimisationof T1-Weighted, T2-Weighted, Dynamic-Enhanced T1-Weighted, Diffusion-Weighted Imaging Apparent Diffusion Coefficient Mapping Sequences and MR Spectroscopy, correlated with biopsy and histopathological findings J Comput Assist Tomogr 2012 36:30-45.10.1097/RCT.0b013e31823f626322261768  [Google Scholar]  [CrossRef]  [PubMed]

[9]Ahmed HU, El-ShaterBosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study Lancet 2017 389:815-822.10.1016/S0140-6736(16)32401-1  [Google Scholar]  [CrossRef]

[10]Song JM, Kim CB, Chung HC, Kane RL, Prostate-specific antigen, digital rectal examination and transrectal ultrasonography: A meta-analysis for this diagnostic triad of prostate cancer in symptomatic Korean men Yonsei Medical Journal 2005 46:414-24.10.3349/ymj.2005.46.3.41415988815  [Google Scholar]  [CrossRef]  [PubMed]

[11]Boukadoum N, Touati R, Demuynck F, Morvan J, Kadi A, Draouat S, Is power Doppler US a good predictor of prostate cancer aggressiveness? J Radiol 2009 90:299-303.10.1016/S0221-0363(09)72508-9  [Google Scholar]  [CrossRef]

[12]Reinsberg SA, Payne GS, Riches SF, Ashley S, Brewster JM, Morgan VA, Combined use of Diffusion-Weighted MRI and 1H MR Spectroscopy to increase accuracy in prostatecancer detection AJR 2007 188:91-98.10.2214/AJR.05.219817179350  [Google Scholar]  [CrossRef]  [PubMed]

[13]XZ Ma, LV K, Sheng JL, Yu YX, Pang PP, Xu MS, Application evaluation of DCE-MRI combined with quantitative analysis of DWI for the diagnosis of prostate cancer Oncology Letters 2019 17(3):3077-84.10.3892/ol.2019.9988  [Google Scholar]  [CrossRef]